National Organization for Rare Disorders: Patients Need the Orphan Drug Act

Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.


You’ll receive updates about new resources, patient stories and insights, advocacy work, and alerts about patient-support events.

The latest about patient advocacy

Join our Email List

Get notified about new stories and resources to empower patients and caregivers.